Theravance Biopharma, Inc.
TBPH•NASDAQ•Healthcare•Biotechnology

About Theravance Biopharma

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). Its late-stage investigational once-daily norepinephrine reuptake inhibitor, Ampreloxetine is in the development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

Company Information

SectorHealthcare
IndustryBiotechnology
CEORick Winningham
Founded2013
Employees97
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock

Contact Information

Websitewww.theravance.com
Phone650 808 6000
Address
901 Gateway Boulevard South San Francisco, California 94080 United States

Corporate Identifiers

CIK0001583107
CUSIPG8807B106
ISINKYG8807B1068
SIC2834

Leadership Team & Key Executives

Rick E. Winningham M.B.A.
Chief Executive Officer and Director
Aziz Sawaf C.F.A.
Senior Vice President and Chief Financial Officer
Brett A. Grimaud Esq.
Senior Vice President, General Counsel and Secretary
Stuart Knight
Senior Vice President of IT&I and Chief Information Officer
Rhonda F. Farnum
Chief Business Officer and Senior Vice President of Commercial and Medical Affairs
Stacy L. Pryce
Senior Vice President and Chief Strategy Officer
Dr. Aine Miller Ph.D.
Senior Vice President of Development and Head of Ireland Office